Des-Tyrosine-γ-Endorphin Administration in Chronic Schizophrenics: A Preliminary Report

C. A. Tamminga, P. J. Tighe, T. N. Chase, E. G. DeFraites, M. H. Schaffer

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


The β-lipotrophin fragment des-tyrosine-γ-endorphin (DTγE) has been reported to have antipsychotic properties. We administered the compound without other psychoactive drugs to a subpopulation of schizophrenic subjects. Male patients with chronic psychotic illness and previous long-term neuroleptic therapy were given DTγE at a similar dose and duration of treatment that have been reported to be effective. No improvement in psychotic symptoms occurred; plasma prolactin level, a parameter characteristically altered by neuroleptic treatment, did not change. The beneficial effects of DTγE in schizophrenia may be specific to a diagnostic category, may be dependent on past pharmacologic treatment, or may occur only in combination with other drugs.

Original languageEnglish (US)
Pages (from-to)167-168
Number of pages2
JournalArchives of General Psychiatry
Issue number2
StatePublished - Feb 1981

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health


Dive into the research topics of 'Des-Tyrosine-γ-Endorphin Administration in Chronic Schizophrenics: A Preliminary Report'. Together they form a unique fingerprint.

Cite this